for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion
Principal Investigator
by Schafer Boeder
Headshot of Schafer Boeder
Schafer Boeder



The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.

Official Title

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk


Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease, Kidney Diseases, Chronic Renal Insufficiency, Diabetes Mellitus, Type 2 Diabetes Mellitus, Insulin Glargine, Orforglipron


You can join if…

Open to people ages 18 years and up

  • Have been diagnosed with type 2 diabetes mellitus (T2DM)
  • Are at least 18 years of age or legal age of consent in the jurisdiction in which the study is taking place, whichever is older.
  • Have HbA1c at screening
    • ≥7.0% and ≤10.5% if background diabetes medication does not include a sulfonylurea, or
    • ≥7.5% and ≤10.5% if background diabetes medication includes a sulfonylurea.
  • Are on stable treatment of at least 1 and no more than 3 oral antihyperglycemic drugs for at least 90 days before screening. Antihyperglycemic drugs may include metformin, SGLT-2 inhibitors, and/or sulfonylureas
  • Have increased risk for cardiovascular (CV) events due to:
  • Are of stable weight (± 5%) for at least 90 days prior to screening
  • Have a BMI ≥25 kilograms per meter squared (kg/m2) at screening

You CAN'T join if...

  • Have type 1 diabetes mellitus
  • Have had chronic or acute pancreatitis any time prior to screening
  • Currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema (e.g. laster photocoagulation or intravitreal injections of anty-VEGF inhibitors
  • Have a known clinically significant gastric emptying abnormality
  • Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or blood alanine transaminase (ALT) or aspartate aminotransferase (AST) enzyme level ≥5.0 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory
  • Have had any of the following within 60 days prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), or hospitalization for congestive heart failure
  • Have an eGFR <15 mL/min/1.73 m2 as determined at screening
  • Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • Have been taking any other diabetes medicines other than metformin, SGLT-2 inhibitors, and/or sulfonylureas during the last 90 days
  • Have used any weight loss drugs, including herbal or nutritional supplements, within 90 days of screening


  • UCSD - Altman Clinical and Translational Research Institute (ACTRI) not yet accepting patients
    La Jolla California 92037 United States
  • Neighborhood Healthcare Institute of Health accepting new patients
    Escondido California 92025 United States

Lead Scientist at UCSD

  • Schafer Boeder
    Assistant Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 16 research publications


accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
Eli Lilly and Company
Phase 3 research study
Study Type
Expecting 2620 study participants
Last Updated